- FDA Accepts Biogen's New Drug Application and Grants Priority ...🔍
- Biogen and Sage Therapeutics Announce FDA Accepts Filing of ...🔍
- FDA accepts new drug application🔍
- Ionis announces that FDA accepts New Drug Application and grants ...🔍
- U.S. FDA accepts Biogen's ALS therapy for review🔍
- FDA Accepts New Drug Application for Tofersen as Treatment of ...🔍
- Eisai Newsroom🔍
- "FDA Accepts Biogen's New Drug Application and Grants ...🔍
FDA Accepts Biogen's New Drug Application and Grants Priority ...
FDA Accepts Biogen's New Drug Application and Grants Priority ...
The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen, an investigational drug for superoxide dismutase 1 (SOD1) ...
Biogen and Sage Therapeutics Announce FDA Accepts Filing of ...
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of ...
FDA accepts new drug application, grants priority review for ALS ...
Biogen Inc. announced that the FDA has accepted a new drug application for tofersen, an investigational drug to treat superoxide dismutase 1 ...
FDA Accepts Biogen's New Drug Application and Grants Priority ...
FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS ... Biogen Inc. ... In this article ...
FDA Accepts Biogen's New Drug Application and Grants Priority ...
Biogen is seeking approval of tofersen under the FDA's accelerated approval pathway, based on the use of neurofilament as a surrogate biomarker.
Ionis announces that FDA accepts New Drug Application and grants ...
The NDA was submitted by Biogen, which licensed tofersen from Ionis in 2018. The application has been granted priority review and given a Prescription Drug User ...
U.S. FDA accepts Biogen's ALS therapy for review - Reuters
The company said the U.S. Food and Drug Administration's decision on its treatment, tofersen, which will go through a priority review, is ...
FDA Accepts New Drug Application for Tofersen as Treatment of ...
The FDA has accepted a new drug application (NDA) for tofersen (Biogen), an investigational drug that treats superoxide dismutase 1 (SOD1) ...
Biogen did not use its Priority Review voucher for the aducanumab BLA. The FDA also stated that it is currently planning to hold an Advisory Committee meeting ...
"FDA Accepts Biogen's New Drug Application and Grants ... - NEALS
"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS," published by Biogen. July ...
FDA grants priority review to Biogen's tofersen for genetic form of ALS
The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Biogen's tofersen, an investigational drug for the ...
Biogen wins FDA priority review for ALS therapy
Biogen says US FDA is reviewing an NDA for tofersen, an investigational drug for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis ...
Biogen and Sage Therapeutics Announce FDA Accepts Filing of
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment ...
Ionis announces that FDA accepts New Drug Application and grants ...
The NDA was submitted by Biogen, which licensed tofersen from Ionis in 2018. The application has been granted priority review and given a ...
Qalsody (tofersen) FDA Approval History - Drugs.com
FDA Approved: Yes (First approved April 25, 2023) ; Brand name: Qalsody ; Generic name: tofersen ; Dosage form: Injection ; Company: Biogen Inc.
FDA Accepts Biogen's New Drug Application and Grants Priority ...
FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS. Globe Newswire - Tue Jul 26, 2022. CAMBRIDGE ...
Biogen's $1.5B Bet for Depressive Disorders Heads to FDA (Updated)
Biogen and its partner, Sage Therapeutics, announced the FDA has accepted the New Drug Application for zuranolone and granted it priority ...
FDA Accepts Biogen's New Drug Application and Grants Priority ...
FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS · Related Stocks · Biogen NewsMORE ...
The FDA accepts license application for aducanumab, the first ...
The Federal U.S. Food and Drug Administration (FDA) accepted the Biologics License Application for aducanumab, an investigational treatment ...
FDA grants priority review for Biogen's Alzheimer's drug - STAT News
The FDA accepted Biogen's Alzheimer's drug submission. Next up, a highly anticipated outside expert review ... The Food and Drug Administration ...